BioLineRx Achieves Major Milestone with GLIX1 in Glioblastoma Clinical Trial

BioLineRx Reports First Quarter 2026 Financial Results and Corporate Update

Introduction
In a significant development, BioLineRx Ltd. (NASDAQ: BLRX) announced its first-quarter results for 2026, coinciding with critical updates on its GLIX1 clinical trial. The company, dedicated to advancing therapies in oncology and rare diseases, has made noteworthy strides, particularly with their latest endeavor targeting glioblastoma, a notoriously aggressive brain tumor.

Clinical Trial Milestone

BioLineRx reached a pivotal milestone by dosing the first patient in the Phase 1/2a clinical trial of GLIX1 for the treatment of glioblastoma. This trial began under the supervision of Dr. Alexandra Miller at NYU Langone Health, marking an essential step in the company’s pipeline. CEO Philip Serlin emphasized the importance of this milestone, stating, “Dosing the first patient in our clinical trial marks a significant achievement for our company and the GLIX1 program.”

The compelling pre-clinical data suggests that GLIX1 has demonstrated a robust anti-tumor effect against glioblastoma across multiple models, including a temozolomide-resistant patient-derived xenograft (PDX) model. This finding underlines GLIX1's potential to address a critical unmet need in treating glioblastoma.

Moreover, BioLineRx will present two abstracts at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, spotlighting GLIX1’s novel mechanism of action and its potential role in combination therapies.

Financial Performance

For the quarter ended March 31, 2026, BioLineRx reported revenues of $0.5 million, a 67% increase from the same period in the previous year, attributed primarily to royalty revenues from their product, APHEXDA. However, the company also posted a net loss of $2.6 million, compared to a net income of $5.1 million in the first quarter of 2025. Despite this, BioLineRx maintained a strong financial position with $17.4 million in cash and short-term deposits, ensuring a cash runway into the first half of 2027.

R&D expenses rose to $2.5 million, primarily driven by costs related to GLIX1 development, reflecting the company's commitment to advancing innovative cancer therapies. Meanwhile, general and administrative expenses saw a slight decrease, resulting from lower legal costs.

Future Outlook

Looking ahead, BioLineRx aims to expand the Phase 1/2a trial to include additional leading cancer centers and potentially add new indications. The primary objective of this trial is to identify a maximum tolerated dose (MTD) and establish a recommended dose based on safety and preliminary efficacy results.

The company also continues to explore the use of GLIX1 in combination with PARP inhibitors, strengthening its commitment to innovative approaches in cancer treatment. Philip Serlin expressed optimism about engaging the oncology community at ASCO, highlighting the potential for GLIX1 not only in glioblastoma but also across multiple cancer types.

Conclusion

In summary, BioLineRx is making significant advances in the field of oncology with GLIX1, which shows promising potential in treating glioblastoma. As they gather momentum in clinical trials and financial performance, the company's direction appears poised for impactful contributions to cancer therapy. Continued updates will follow as BioLineRx navigates through these critical stages of drug development and corporate growth.